Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50M
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
47M
-
Shares change
-
+9.99M
-
Total reported value, excl. options
-
$557M
-
Value change
-
+$118M
-
Put/Call ratio
-
1.14
-
Number of buys
-
77
-
Number of sells
-
-47
-
Price
-
$11.86
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q1 2024
153 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q1 2024.
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47M shares
of 50M outstanding shares and own 93.96% of the company stock.
Largest 10 shareholders include VR Adviser, LLC (6.25M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (4.19M shares), TANG CAPITAL MANAGEMENT LLC (4.13M shares), Frazier Life Sciences Management, L.P. (3.69M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.58M shares), BlackRock Inc. (2.43M shares), VANGUARD GROUP INC (1.69M shares), Boxer Capital, LLC (1.59M shares), Capital World Investors (1.46M shares), and Saturn V Capital Management LP (1.44M shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.